Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Rahul Aggarwal , Dirk Müller-Wieland Added: 2 months ago
Filmed onsite at EASD 2025, this on-demand series features key insights from Prof Dirk Müller-Wieland and Dr Rahul Aggarwal to interpret the latest data on eicosapentaenoic acid(EPA), including the latest sub-analysis of the REDUCE-IT trial, whichanalysed the effectiveness of icosapent ethyl (IPE) on CV risk by triglyceride-glucose (TyG) index - an indicator of insulin resistance and risk of type… View more
Job title: President, Foundation–Medical Research Institutes, Geneva and Professor, Lebanese University of Medicine, Beirut
Dr Roland Asmar is president of the "Foundation-Medical research Institutes", and past-President of the "Cardiovascular Institute", Paris, France. Prior to this position, he was past president, of the French spoken network of hypertension, and the International Society of Vascular Health. Dr Asmar developed his clinical research activities in different research units at Broussais Hospital and… View more
Job title: President Elect
Dr George L. Bakris, MD, is a distinguished member of the National Kidney Foundation's Board of Directors. As the Professor of Medicine and Director of the Comprehensive Hypertension Center at the University of Chicago Medicine, he brings a wealth of expertise to the forefront of medical education.Previously serving as the Vice-Chairman of Preventive Medicine and Director of the Rush University… View more
Author(s): Ahran D Arnold Added: 3 months ago
ESC Congress 2025 - EMORI-HCM finds that right ventricular pacing (iRVP) improves symptoms in obstructive hypertrophic cardiomyopathy (oHCM) patients.Dr Ahran Arnold (Imperial College London, UK) discusses findings from the EMORI-HCM study, exploring electro-mechanically optimised right ventricular pacing as a novel therapeutic approach for patients with oHCM.This interventional trial examined… View more
Added: 4 months ago Source:  Radcliffe Cardiology
The long-term utility of beta-blockers following an uncomplicated myocardial infarction (MI) remains a subject of clinical debate. New secondary results from the AβYSS trial (Assessment of β-blocker interruption one Year after an uncomplicated myocardial infarction on Safety and Symptomatic cardiac events requiring hospitalization) reveal that interrupting this therapy leads to sustained… View more
Author(s): Gerhard Hindricks , Faizel Osman , Keitaro Senoo , et al Added: 2 years ago
This video series page covers content associated with Atrial Fibrillation.AFib is associated with a 5x greater risk of stroke, however with effective treatment, the risk of stroke can be reduced.¹ The lifetime risk for AFib is 1 in 3 individuals² and it often occurs with hypertension. Early detection is key, to allow for prompt and satisfactory disease management to not only control symptoms but… View more